Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1809 1
1810 1
1815 1
1819 2
1843 1
1852 2
1853 1
1887 1
1889 3
1892 1
1893 2
1894 1
1897 2
1898 1
1899 1
1900 1
1902 5
1903 4
1904 1
1905 3
1906 1
1908 3
1909 2
1910 3
1911 3
1912 4
1913 2
1914 1
1915 1
1916 10
1918 1
1919 2
1920 2
1921 1
1922 2
1923 2
1925 1
1928 2
1929 1
1930 3
1931 5
1932 9
1933 1
1934 1
1935 3
1936 4
1937 1
1938 1
1939 1
1940 3
1941 1
1942 2
1944 1
1945 4
1946 11
1947 15
1948 26
1949 23
1950 20
1951 31
1952 21
1953 21
1954 20
1955 25
1956 20
1957 26
1958 35
1959 24
1960 32
1961 37
1962 34
1963 53
1964 57
1965 50
1966 78
1967 65
1968 70
1969 94
1970 107
1971 94
1972 96
1973 114
1974 117
1975 98
1976 148
1977 157
1978 152
1979 173
1980 221
1981 209
1982 225
1983 214
1984 214
1985 209
1986 208
1987 246
1988 220
1989 240
1990 253
1991 216
1992 291
1993 248
1994 261
1995 257
1996 250
1997 250
1998 245
1999 284
2000 296
2001 287
2002 301
2003 301
2004 367
2005 343
2006 389
2007 368
2008 406
2009 387
2010 464
2011 433
2012 496
2013 523
2014 576
2015 554
2016 596
2017 602
2018 559
2019 575
2020 650
2021 665
2022 582
2023 564
2024 163

Text availability

Article attribute

Article type

Publication date

Search Results

17,295 results

Results by year

Filters applied: . Clear all
Page 1
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K. Agarwal N, et al. Among authors: jones rj. Lancet. 2023 Jul 22;402(10398):291-303. doi: 10.1016/S0140-6736(23)01055-3. Epub 2023 Jun 4. Lancet. 2023. PMID: 37285865 Clinical Trial.
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG; BMT CTN 1703 Investigators. Bolaños-Meade J, et al. Among authors: jones rj. N Engl J Med. 2023 Jun 22;388(25):2338-2348. doi: 10.1056/NEJMoa2215943. N Engl J Med. 2023. PMID: 37342922 Free PMC article. Clinical Trial.
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP. Glaviano A, et al. Among authors: jones rh. Mol Cancer. 2023 Aug 18;22(1):138. doi: 10.1186/s12943-023-01827-6. Mol Cancer. 2023. PMID: 37596643 Free PMC article. Review.
Epigenetic memory of coronavirus infection in innate immune cells and their progenitors.
Cheong JG, Ravishankar A, Sharma S, Parkhurst CN, Grassmann SA, Wingert CK, Laurent P, Ma S, Paddock L, Miranda IC, Karakaslar EO, Nehar-Belaid D, Thibodeau A, Bale MJ, Kartha VK, Yee JK, Mays MY, Jiang C, Daman AW, Martinez de Paz A, Ahimovic D, Ramos V, Lercher A, Nielsen E, Alvarez-Mulett S, Zheng L, Earl A, Yallowitz A, Robbins L, LaFond E, Weidman KL, Racine-Brzostek S, Yang HS, Price DR, Leyre L, Rendeiro AF, Ravichandran H, Kim J, Borczuk AC, Rice CM, Jones RB, Schenck EJ, Kaner RJ, Chadburn A, Zhao Z, Pascual V, Elemento O, Schwartz RE, Buenrostro JD, Niec RE, Barrat FJ, Lief L, Sun JC, Ucar D, Josefowicz SZ. Cheong JG, et al. Among authors: jones rb. Cell. 2023 Aug 31;186(18):3882-3902.e24. doi: 10.1016/j.cell.2023.07.019. Epub 2023 Aug 18. Cell. 2023. PMID: 37597510
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
Smith RM, Jones RB, Specks U, Bond S, Nodale M, Al-Jayyousi R, Andrews J, Bruchfeld A, Camilleri B, Carette S, Cheung CK, Derebail V, Doulton T, Ferraro A, Forbess L, Fujimoto S, Furuta S, Gewurz-Singer O, Harper L, Ito-Ihara T, Khalidi N, Klocke R, Koening C, Komagata Y, Langford C, Lanyon P, Luqmani R, McAlear C, Moreland LW, Mynard K, Nachman P, Pagnoux C, Peh CA, Pusey C, Ranganathan D, Rhee RL, Spiera R, Sreih AG, Tesar V, Walters G, Wroe C, Jayne D, Merkel PA; RITAZAREM co-investigators. Smith RM, et al. Among authors: jones rb. Ann Rheum Dis. 2023 Jul;82(7):937-944. doi: 10.1136/ard-2022-223559. Epub 2023 Mar 23. Ann Rheum Dis. 2023. PMID: 36958796 Free PMC article. Clinical Trial.
Aging Fly Cell Atlas identifies exhaustive aging features at cellular resolution.
Lu TC, Brbić M, Park YJ, Jackson T, Chen J, Kolluru SS, Qi Y, Katheder NS, Cai XT, Lee S, Chen YC, Auld N, Liang CY, Ding SH, Welsch D, D'Souza S, Pisco AO, Jones RC, Leskovec J, Lai EC, Bellen HJ, Luo L, Jasper H, Quake SR, Li H. Lu TC, et al. Among authors: jones rc. Science. 2023 Jun 16;380(6650):eadg0934. doi: 10.1126/science.adg0934. Epub 2023 Jun 16. Science. 2023. PMID: 37319212 Free PMC article.
Ketolysis drives CD8+ T cell effector function through effects on histone acetylation.
Luda KM, Longo J, Kitchen-Goosen SM, Duimstra LR, Ma EH, Watson MJ, Oswald BM, Fu Z, Madaj Z, Kupai A, Dickson BM, DeCamp LM, Dahabieh MS, Compton SE, Teis R, Kaymak I, Lau KH, Kelly DP, Puchalska P, Williams KS, Krawczyk CM, Lévesque D, Boisvert FM, Sheldon RD, Rothbart SB, Crawford PA, Jones RG. Luda KM, et al. Among authors: jones rg. Immunity. 2023 Sep 12;56(9):2021-2035.e8. doi: 10.1016/j.immuni.2023.07.002. Epub 2023 Jul 28. Immunity. 2023. PMID: 37516105 Free article.
LKB1 controls inflammatory potential through CRTC2-dependent histone acetylation.
Compton SE, Kitchen-Goosen SM, DeCamp LM, Lau KH, Mabvakure B, Vos M, Williams KS, Wong KK, Shi X, Rothbart SB, Krawczyk CM, Jones RG. Compton SE, et al. Among authors: jones rg. Mol Cell. 2023 Jun 1;83(11):1872-1886.e5. doi: 10.1016/j.molcel.2023.04.017. Epub 2023 May 11. Mol Cell. 2023. PMID: 37172591 Free article.
The biology and treatment of leiomyosarcomas.
Kerrison WGJ, Thway K, Jones RL, Huang PH. Kerrison WGJ, et al. Among authors: jones rl. Crit Rev Oncol Hematol. 2023 Apr;184:103955. doi: 10.1016/j.critrevonc.2023.103955. Epub 2023 Mar 7. Crit Rev Oncol Hematol. 2023. PMID: 36893945 Free article. Review.
Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis.
Benichou N, Charles P, Terrier B, Jones RB, Hiemstra T, Mouthon L, Bajema I, Berden A, Thervet E, Guillevin L, Jayne D, Karras A; French Vasculitis Study Group (FVSG) and European Vasculitis Society (EUVAS) investigators. Benichou N, et al. Among authors: jones rb. Kidney Int. 2023 Jun;103(6):1144-1155. doi: 10.1016/j.kint.2023.02.029. Epub 2023 Mar 20. Kidney Int. 2023. PMID: 36940799 Clinical Trial.
17,295 results
You have reached the last available page of results. Please see the User Guide for more information.